THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Friday, November 04, 2022
Immunotherapy is beneficial in curing cancer patients as it targets the immune system instead of tumor cells.
FREMONT, CA: Immunotherapy revolutionizes cancer treatment. It's a novel cancer treatment. It targets the immune system, not tumor cells. This method has been quite successful and has helped us think of metastatic cancer patients as being cured.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Immunotherapy from basic science
Basic scientific advances make immunotherapy beneficial. We've wanted to use the immune system in cancer treatment for 100 years. We failed because we lacked the fundamentals.
We only realized we could block inhibitory pathways once we learned how positive and negative stimulatory chemicals regulate T cells. Nobel Laureate James Allison, PhD, discovered it. Clinical success depends on that solid basis.
T cells are crucial, but other immune cells are too. Targeting immune cell subsets with their own regulatory mechanisms and therapeutic targets is crucial.
Synergistic cancer treatments
It requires a combination of techniques to succeed. Surgery, chemotherapy, radiation, and targeted medicines attack cancer cells. Immunotherapy targets immune cells. Combining these treatments can weaken the tumor and stimulate the immune system to remove cancer permanently.
A tumor has many more parts than cancer cells. Immune, stromal, and fibroblast cells comprise the tumor microenvironment. These parts perform various roles in different cancers. With the correct combination strategy for a tumor, we can target these microenvironment components for long-term patient benefit.
Cancer care's future
Understanding a tumor is the vision of a future patient.
We might analyze circulating tumor cells and their surroundings with a blood sample liquid biopsy. We can apply targeted therapy for a tumor mutation.
We can also learn if their tumor has many myeloid cells, which can damage the immune system. We need a myeloid cell-blocking medication with our targeted therapy. We could use immunotherapy to enhance T-cell activation and destroy the tumor.
These treatments should work together according to each patient and their malignancy. It doesn't treat breast or prostate cancer. It targets a tumor and the immune system.
Culture and innovation drive immunotherapy research.
Our approach values diversity. Our upbringing shapes our ideas and thinking. Unique insights can flip a notion or reframe facts, leading to the next breakthrough. We must support exceptional research across backgrounds since we are still determining where the next amazing idea will come from.
More in News